Literature DB >> 27156931

Tocilizumab for systemic sclerosis: implications for future trials.

Oliver Distler1, Jörg H W Distler2.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2016        PMID： 27156931     DOI： 10.1016/S0140-6736(16)00622-X

Source DB:  PubMed          Journal:  Lancet        ISSN： 0140-6736            Impact factor:   79.321


× No keyword cloud information.
  2 in total

1.  Parry Romberg disease with En Coup de Sabre Scleroderma: Effect of tocilizumab on periodontal bone inflammation.

Authors:  Thaís Cugler Meneghetti; Juliana Yassue Barbosa da Silva; Lúcio Eduardo Kluppel; Vânia Oliveira de Carvalho
Journal:  J Scleroderma Relat Disord       Date:  2020-11-25

2.  Safety and efficacy of subcutaneous tocilizumab in systemic sclerosis: results from the open-label period of a phase II randomised controlled trial (faSScinate).

Authors:  Dinesh Khanna; Christopher P Denton; Celia J F Lin; Jacob M van Laar; Tracy M Frech; Marina E Anderson; Murray Baron; Lorinda Chung; Gerhard Fierlbeck; Santhanam Lakshminarayanan; Yannick Allanore; Janet E Pope; Gabriela Riemekasten; Virginia Steen; Ulf Müller-Ladner; Helen Spotswood; Laura Burke; Jeffrey Siegel; Angelika Jahreis; Daniel E Furst
Journal:  Ann Rheum Dis       Date:  2017-10-24       Impact factor: 19.103
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.